Data Insights

Erdafitinib by Johnson & Johnson for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Erdafitinib by Johnson & Johnson for Soft Tissue Sarcoma: Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Soft Tissue Sarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Soft Tissue Sarcoma

Data Insights

Erdafitinib by Johnson & Johnson for Esophageal Cancer: Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Esophageal Cancer

Data Insights

Erdafitinib by Johnson & Johnson for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Erdafitinib by Johnson & Johnson for Gastric Cancer: Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Gastric Cancer

Data Insights

Erdafitinib by Johnson & Johnson for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Non Muscle Invasive Bladder Cancer...

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

Data Insights

Erdafitinib by Johnson & Johnson for Non-Hodgkin Lymphoma: Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Non-Hodgkin Lymphoma

Data Insights

Erdafitinib by Johnson & Johnson for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Squamous Non-Small Cell Lung Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Squamous Non-Small Cell Lung Cancer

Data Insights

Erdafitinib by Johnson & Johnson for Non-Small Cell Lung Cancer: Likelihood of Approval

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Non-Small Cell Lung Cancer